• PDF: Delivered by email usually within 4 to 8 UK business hours.

Mexico Pharmaceuticals and Healthcare Report Q2 2013

  • Publication Date:February 2013
  • Publisher:Business Monitor
  • Product Type: Report
  • Pages:133
  • ISBN:178027

Mexico Pharmaceuticals and Healthcare Report Q2 2013

Includes 3 FREE quarterly updates

BMI View: Mexico's relatively low-cost business environment, growing domestic pharmaceutical market
and the improving regulatory regime have made it an attractive market to multinationals The improved
performance by market regulator COFEPRIS has allowed Mexico to acquire a reputation for early,
speedy approvals of medicines that meet urgent local epidemiological needs and allow direct access to
other robust growing pharmaceutical markets in Latin America

Headline Expenditure Projections

Pharmaceuticals: MXN176 00bn (US$13 36bn) in 2012 to MXN191 58bn (US$14 97bn) in 2013;
+8 9% in local currency terms and +12% in US dollar terms Forecasts increasefrom Q113 due to
improving industry environment
Healthcare: MXN965 46bn (US$73 31bn) in 2012 to MXN1,046 9bn (US$81 79bn) in 2013; +8 4% in
local currency terms and +11 6% in US dollar terms Forecasts increase from Q113 due to improving
industry environment
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Business Environment 13
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales Indicators 2009-2017 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Indicators 2009-2017 18
Table: Healthcare Governmental Indicators 2009-2017 18
Table: Healthcare Private Indicators 2009-2017 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Sales Indicators 2009-2017 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators 2009-2017 23
Generic Drug Market Forecast 24
Table: Generic Drug Sales Indicators, 2009-2017 26
OTC Drug Market Forecast 27
Table: OTC Medicine Sales Indicators 2009-2017 29
Pharmaceutical Trade Forecast 30
Table: Trade Indicators 2009-2017 31
Other Healthcare Data Forecasts 32
Key Risks To BMI's Forecast Scenario 32
Economic Analysis 34
Table: MEXICO - GDP CONTRIBUTION TO GROWTH 40
Industry Risk Reward Ratings 41
Table: Americas Pharmaceutical And Healthcare Risk/Reward Ratings, Q213 41
Rewards 42
Risks 42
Market Overview 44
Industry Trends And Developments 46
Epidemiology 46
Healthcare Sector Funding 50
Medical Tourism 50
Research & Development 51
Clinical Trials 52
Table: Clinical Trial Regulation In Mexico 54
Regulatory Development 56
Regulatory Development 56
Biologics And Biosimilar Guidelines 59
Intellectual Property Issues 64
Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights 67
Counterfeit Drugs 68
Pricing & Reimbursement 69
Reimbursement 71
Pricing Issues 72
Other Regulatory Developments 76
Competitive Landscape 78
Pharmaceutical Sector 78
Domestic Industry 79
Table: AstraZeneca Sales, 2005-10 79
Pharmaceutical Distribution 85
Pharmaceuticals Retail Sector 87
Table: IMSS Financial Indicators, 2000-11 (MXNmn) 88
Table: SPSS Budget, 2004-11 (MXNmn) 90
Other Developments 91
Company Profile 92
Genomma Labs 92
Pfizer 97
GlaxoSmithKline (GSK) 100
Sanofi 103
Eli Lilly 106
Bristol-Myers Squibb 109
Novartis 111
Bayer 114
Boehringer Ingelheim 116
Merck KGaA 119
Roche Syntex 122
Demographic Forecast 125
Mexico Demographic Data 125
Table: Mexico's Population By Age Group, 1990-2020 ('000) 126
Table: Mexico's Population By Age Group, 1990-2020 (% of total) 127
Table: Mexico's Key Population Ratios, 1990-2020 128
Table: Mexico's Rural And Urban Population, 1990-2020 128
Glossary 129
Methodology 131
Methodology 131
Risk/Reward Ratings Methodology 131
Ratings Overview 132
Table: Pharmaceutical Business Environment Indicators 132
Weighting 133
Table: Weighting Of Components 133
Sources 133
+44 20 8816 8548

Ask a question about Mexico Pharmaceuticals and Healthcare Report Q2 2013

Enter the characters you see in the picture below
Captcha